Interview with the President and CEO: AVROBIO, Inc. (NASDAQ:AVRO)
Geoff MacKay is President and Chief Executive Officer of AVROBIO, Inc. Mr. MacKay is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Mr. MacKay was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Mr. MacKay spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the board of MassBio, Chairman of the board of the Alliance of Regenerative Medicine and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Mr. MacKay is dedicated to applying innovation to reshape and improve the quality of health care. Profile
Word count: 3,272
TWST: What is AVROBIO and its core technology platform?
Mr. MacKay: AVROBIO is a gene therapy company that develops potential cures for